Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.

• Egile Nagusiak: Romain Guery (Egilea), Benoit Henry (Egilea), Guillaume Martin-Blondel (Egilea), Claire Rouzaud (Egilea), Florence Cordoliani (Egilea), Gundel Harms (Egilea), Jean-Pierre Gangneux (Egilea), Françoise Foulet (Egilea), Emmanuelle Bourrat (Egilea), Michel Baccard (Egilea), Gloria Morizot (Egilea), Paul-Henri Consigny (Egilea), Antoine Berry (Egilea), Johannes Blum (Egilea), Olivier Lortholary (Egilea), Pierre Buffet (Egilea), French Cutaneous Leishmaniasis Study group & the LeishMan network (Egilea)
• Formatua: Liburua
• Argitaratua: Public Library of Science (PLoS), 2017-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for a solid clinical benefit in this indication.We conducted a retrospective analysis of data from a French centralized referral treatment program...